Introduction Studies investigating rates and risk factors for serious safety events (SSEs)
during rituximab treatment of multiple sclerosis (MS), neuromyelitis optica spectrum …

Introduction Multiple sclerosis (MS) is an immune-mediated disease. Over the last decades
therapeutic options have broadened tremendously. Nevertheless, various therapeutic …

Objectives Multiple sclerosis (MS) is an immune-mediated disease of the central nervous
system. B cells play an important pathogenic role in MS. Rituximab (RTX), a B-cell depleting …

Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS).
More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo …

Objectives Off‐label use of rituximab to treat MS patients in Sweden is high, and the need for
long‐term safety data may not be met. Our objectives were to assess the rate of rituximab …

Background: Rituximab and ocrelizumab are anti-CD20 monoclonal antibodies that have
shown a marked reduction in multiple sclerosis (MS) inflammatory activity. However, their …

Objective: To investigate the safety and efficacy of rituximab in multiple sclerosis (MS).
Methods: In this retrospective uncontrolled observational multicenter study, off-label …

Objectives The use of rituximab (RTX) in multiple sclerosis (MS) is a rapidly increasing
choice of disease‐modifying therapy. Efficacy outside specialized university hospital‐based …

Objective To investigate the effect of rituximab, a B-cell targeted therapy that is used in the
treatment of multiple sclerosis (MS) and neuromyelitis optica (NMO), on other immune cells …

Importance Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B
cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared …